North America is the largest region in the global IVF syringes market, accounting for 34% of 2025 revenue, or USD 0.47 billion. Contrive Datum Insights projects that figure to reach USD 0.99 billion by 2034.
Market size and how the regions compare
The global market was valued at USD 1.38 billion in 2025. It is projected to grow from USD 1.52 billion in 2026 to USD 3.2 billion by 2034, a compound annual growth rate of 9.75% over the forecast period.
IVF syringes are sterile, single-use devices that draw and administer the hormone medications used in in vitro fertilization, in both intramuscular and subcutaneous formats. Fertility clinics and hospital reproductive medicine units buy them. Patients increasingly do too, for home administration of stimulation and luteal-support injections under a clinician's prescribed protocol.
Asia Pacific is the region closing in. Its share rises from 26% in 2025 to 32% in 2034, and its revenue grows from USD 0.36 billion to USD 1.02 billion, which ends the period above North America's USD 0.99 billion. Middle East and Africa stays the smallest region, at 6% of revenue in 2025 and 6% in 2034. At the country level, the United States is the largest single market, at USD 0.4 billion in 2025 and 29% of global revenue.
Segments, and the risk to North America's lead
By type, Subcutaneous Injection holds 62.32% of 2025 revenue, worth USD 0.86 billion. It also grows fastest, at 10.94%, lifting its share to 68.13% and its value to USD 2.18 billion by 2034. Intramuscular Injection carries 37.68% of 2025 revenue and grows at 7.55%.
The other segment axes show the same split between where revenue sits today and where it is moving:
- Application: Fertility Clinics led in 2025 with 54.35% of revenue at USD 0.75 billion, while Homecare Settings grows fastest at 15.38%.
- Syringe design: Conventional Syringes led with 57.97% at USD 0.8 billion; Prefilled Syringes grows fastest at 12.4%.
- Material: Plastic/Polypropylene led with 71.01% at USD 0.98 billion.
- Distribution channel: Direct/Institutional Sales led with 65.94% at USD 0.91 billion; Online Pharmacies grows fastest at 15.45%.
The study names rising global infertility prevalence and delayed childbearing as the largest single contributor to growth, and rates its impact high. The main risk sits in cost. The bear case assumes that reimbursement expansion stalls and that out-of-pocket pressure slows IVF cycle-start growth in the largest markets, leaving 2034 revenue at USD 2.64 billion. The bull case assumes broader reimbursement coverage in more countries and faster uptake of prefilled, home-administered formats, which would lift 2034 revenue to USD 3.84 billion against the USD 3.2 billion base case.
North America's position depends on which of those paths plays out. The United States is the largest country market, so a stall in the largest markets would bear directly on the region's lead. Asia Pacific is already projected to finish ahead in revenue by 2034, and a weaker North American outcome would only bring that crossover closer.
The report covers five segmentation axes (type, application, syringe design, material and distribution channel), with revenue and growth rates for every line in every year from 2020 to 2034. It also covers all five regions with country-level breakdowns, the competitive landscape and the research methodology. It is delivered as a PDF, and a free sample is available on request.